Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

References

• American Cancer Society. Cancer Facts and Figures. 2006, Available at: http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2006_Presentation.asp. Accessed January 19, 2007
   Google Scholar
• SEER Cancer Statistics Review, 1975 – 2003, L AG Ries, D Harkins, M Krapcho, A Mariotto, B A Miller, E J Feuer, et al. National Cancer Institute, Bethesda, MD 2007, Available at: http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006. Accessed January 19
   Google Scholar
• Horning S J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20(Suppl 5)75–88
   PubMed Web of Science ®Google Scholar
• Gallagher C J, Gregory W M, Jones A E, Stansfeld A G, Richards M A, Dhaliwal H S, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Johnson P W, Rohatiner A Z, Whelan J S, Price C G, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Davis T A, Kaminski M S, Leonard J P, Hsu F J, Wilkinson M, Zelenetz A, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10: 7792–7798
   PubMed Web of Science ®Google Scholar
• Alcindor T, Witzig T E. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2002; 3: 275–282
   PubMedGoogle Scholar
• Wagner H N, Jr, Wiseman G A, Marcus C S, Nabi H A, Nagle C E, Fink-Bennett D M, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43: 267–272
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Gordon L I, Wiseman G A, Emmanouilides C, Murray J L, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 1263–1270
   PubMed Web of Science ®Google Scholar
• Cheung M C, Haynes A E, Stevens A, Meyer R M, Imrie K, Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma 2006; 47: 967–977
   PubMed Web of Science ®Google Scholar
• Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98–101
   PubMedGoogle Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Emmanouilides C, Darif M, Witzig T E, Gordon L I, Revell S, et al. Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy (RIT). Blood 2006; 108, Abstract 485
   Google Scholar
• Wiseman G A, Kornmehl E, Leigh B, Erwin W D, Podoloff D A, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44: 465–474
   PubMed Web of Science ®Google Scholar
• Ansell S M, Ristow K M, Habermann T M, Wiseman G A, Witzig T E. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3885–3890
   PubMed Web of Science ®Google Scholar
• Ansell S M, Schilder R J, Pieslor P C, Gordon L I, Emmanouilides C, Vo K, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 2004; 5: 202–204
   PubMedGoogle Scholar
• Kaminski M S, Radford J A, Gregory S A, Leonard J P, Knox S J, Kroll S, Wahl R L. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005; 23: 7985–7993, Erratum in J Clin Oncol 2006;24:212
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Wiseman G A, Gordon L I, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, Witzig T E, Spies S, Bartlett N L, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253, Erratum in J Clin Oncol 2000;18:2351
   PubMed Web of Science ®Google Scholar
• Jacobs S A, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11(19 Part 2)7146s–7150s
   Google Scholar
• Witzig T E, Wiseman G A, Geyer S M, Colgan J P, Inwards D J, Micallef I N, et al. A phase I trial of two-sequential doses of Zevalin™ radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood 2003; 102: 406a, Abstract 1475
   Google Scholar
• Witzig T E, Emmanouilides C E, Molina A, Gordon L I, Gaston I, Flinn W, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2003; 22: 597, Abstract 2400
   Google Scholar
• Emmanouilides C E, Witzig T E, Molina A, Gordon L I, Multani P, Wiseman G A, et al. Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade follicular, and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2003; 22: 595, Abstract 2392
   Google Scholar
• Witzig T E, Flinn I W, Gordon I, Emmanouilides C E, Czuczman M, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar